Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Active, not recruiting · NCT05685004 · Registry updated 2026-09-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) | brain glioblastoma | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-29 | NCT05685004 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| TVAX Biomedical | 1 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Capital Health | Pennington | United States | 3 |
| Cedar-Sanai Medical Center | Los Angeles | United States | 1 |
| Center for Neurosciences | Tucson | United States | 19 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Piedmont | Atlanta | United States | 5 |
| Providence St. Vincent | Portland | United States | 2 |
| University of Kansas Medical Center | Kansas City | United States | 1 |
| University of Southern California Keck School of Medicine | Los Angeles | United States | 1 |